

Pompe Disease Treatment Market by Treatment (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone-Advanced Replacement Therapy (CART), and Others), Route of Administration (Oral, Intravenous, and Others), Distribution Channel (Hospital and Clinics Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Indication Type (Infantile-Onset Pompe Disease (IOPD), Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Pompe Disease (LOPD), and Others), and Region 2024-2032

Market Report | 2024-01-30 | 142 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$3899.00
- Five User Licence \$4899.00
- Enterprisewide License \$5899.00

Report description:

The global Pompe disease treatment market size reached US\$ 1.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 1.3 Billion by 2032, exhibiting a growth rate (CAGR) of 2.58% during 2024-2032. The increasing number of clinical studies and trials, the rising popularity of ERT, and the growing number of patients suffering from Pompe disease represent some of the key factors driving the market.

Pompe disease is a genetic disorder caused by the buildup of a complex sugar known as glycogen in the cells of the body, which affects organs, tissues, and muscles. It is an autosomal recessive glycogen storage syndrome caused by the deficiency of lysosomal enzyme acid a-glucosidase (GAA). It is associated with weak muscles, enlarged liver, trouble breathing, hearing problem, lung infection, irregular heartbeat, and losing weight. It is diagnosed using various tools and tests, including electromyography, X-rays, and magnetic resonance imaging (MRI). Pompe disease can be treated using medications, enzyme replacement therapy (ERT), substrate reduction therapy (SRT), chaperone-advanced replacement therapy (CART), and injections,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

which aid in improving the quality of life.

Pompe Disease Treatment Market Trends:

There is a considerable rise in the prevalence of genetic abnormalities among individuals and an increase in the number of patients suffering from Pompe disease. This, coupled with the growing Pompe disease among infants and increasing concerns among parents about the health of their newborns, represents one of the key factors bolstering the growth of the market. Moreover, the growing geriatric population that is susceptible to developing these medical disorders is resulting in an increasing demand for Pompe disease treatment. In addition, the expanding number of clinical studies and trials to develop new treatments for Pompe disease is influencing the market positively. Apart from this, the rising awareness among people about ERT for curing Pompe disease is favoring the market growth. Furthermore, there is an increase in awareness about various treatments, including stem cell transplant, bone marrow transplantation, chemotherapy, and immunotherapy, on account of their numerous advantages. This, along with the awareness about the easy availability of ERT treatment alternatives like lumizyme, is creating a positive outlook for the market. Besides this, there is a rise in the adoption of health insurance policies that provide financial assistance and minimize healthcare expenditure for Pompe disease treatment. Additionally, governments and non-governmental organizations (NGOs) of numerous countries are undertaking measures to offer quality healthcare facilities that are accessible to all. This, along with significant improvements in the diagnostic technologies, is anticipated to provide a favorable outlook to the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global Pompe disease treatment market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on treatment, route of administration, distribution channel, and indication type.

Treatment Insights:

Enzyme Replacement Therapy (ERT)
Substrate Reduction Therapy (SRT)
Chaperone-Advanced Replacement Therapy (CART)
Others

The report has provided a detailed breakup and analysis of the Pompe disease treatment market based on the treatment. This includes enzyme replacement therapy (ERT), substrate reduction therapy (SRT), chaperone-advanced replacement therapy (CART), and others. According to the report, enzyme replacement therapy (ERT) represented the largest segment.

Route of Administration Insights:

Oral
Intravenous
Others

A detailed breakup and analysis of the Pompe disease treatment market based on the route of administration has also been provided in the report. This includes oral, intravenous, and others.

Distribution Channel Insights:

Hospital and Clinics Pharmacies
Retail Pharmacies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Online Pharmacies

Others

A detailed breakup and analysis of the Pompe disease treatment market based on the distribution channel has also been provided in the report. This includes hospital and clinics, retail, and online pharmacies, and others. According to the report, hospital and clinics pharmacies accounted for the largest market share.

Indication Type Insights:

Infantile-Onset Pompe Disease (IOPD)

Classic Infantile Form

Non-Classic Infantile Form

Late-Onset Pompe Disease (LOPD)

Others

A detailed breakup and analysis of the Pompe disease treatment market based on the indication type has also been provided in the report. This includes infantile-onset Pompe disease (IOPD), classic infantile form, non-classic infantile form, late-onset Pompe disease (LOPD), and others. According to the report, late-onset Pompe disease (LOPD) accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for Pompe disease treatment. Some of the factors driving the North America Pompe disease treatment market included the growing awareness about various alternative treatments, increasing number of clinical studies and trials, and well-established healthcare facilities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global Pompe disease treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amicus Therapeutics Inc., Audentes Therapeutics Inc. (Astellas US Holding Inc.), Oxyrane UK Limited, Sanofi S.A., Spark Therapeutics Inc, etc.

Key Questions Answered in This Report:

How has the global Pompe disease treatment market performed so far and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global Pompe disease treatment market?

What are the key regional markets?

Which countries represent the most attractive Pompe disease treatment markets?

What is the breakup of the market based on the treatment?

What is the breakup of the market based on the route of administration?

What is the breakup of the market based on the distribution channel?

What is the breakup of the market based on the indication type?

What is the competitive structure of the global Pompe disease treatment market?

Who are the key players/companies in the global Pompe disease treatment market?

Table of Contents:

1	Preface
2	Scope and Methodology
2.1	Objectives of the Study
2.2	Stakeholders
2.3	Data Sources
2.3.1	Primary Sources
2.3.2	Secondary Sources
2.4	Market Estimation
2.4.1	Bottom-Up Approach
2.4.2	Top-Down Approach
2.5	Forecasting Methodology
3	Executive Summary
4	Introduction
4.1	Overview
4.2	Key Industry Trends
5	Global Pompe Disease Treatment Market
5.1	Market Overview
5.2	Market Performance
5.3	Impact of COVID-19
5.4	Market Forecast
6	Market Breakup by Treatment
6.1	Enzyme Replacement Therapy (ERT)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Substrate Reduction Therapy (SRT)
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 6.3 Chaperone-Advanced Replacement Therapy (CART)
 - 6.3.1 Market Trends
 - 6.3.2 Market Forecast
- 6.4 Others
 - 6.4.1 Market Trends
 - 6.4.2 Market Forecast
- 7 Market Breakup by Route of Administration
 - 7.1 Oral
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
 - 7.2 Intravenous
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
 - 7.3 Others
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast
- 8 Market Breakup by Distribution Channel
 - 8.1 Hospital & Clinics Pharmacies
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
 - 8.2 Retail Pharmacies
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
 - 8.3 Online Pharmacies
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast
 - 8.4 Others
 - 8.4.1 Market Trends
 - 8.4.2 Market Forecast
- 9 Market Breakup by Indication Type
 - 9.1 Infantile-Onset Pompe Disease (IOPD)
 - 9.1.1 Market Trends
 - 9.1.2 Market Forecast
 - 9.2 Classic Infantile Form
 - 9.2.1 Market Trends
 - 9.2.2 Market Forecast
 - 9.3 Non-Classic Infantile Form
 - 9.3.1 Market Trends
 - 9.3.2 Market Forecast
 - 9.4 Late-Onset Pompe Disease (LOPD)
 - 9.4.1 Market Trends
 - 9.4.2 Market Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.5 Others
 - 9.5.1 Market Trends
 - 9.5.2 Market Forecast
- 10 Market Breakup by Region
 - 10.1 North America
 - 10.1.1 United States
 - 10.1.1.1 Market Trends
 - 10.1.1.2 Market Forecast
 - 10.1.2 Canada
 - 10.1.2.1 Market Trends
 - 10.1.2.2 Market Forecast
 - 10.2 Asia-Pacific
 - 10.2.1 China
 - 10.2.1.1 Market Trends
 - 10.2.1.2 Market Forecast
 - 10.2.2 Japan
 - 10.2.2.1 Market Trends
 - 10.2.2.2 Market Forecast
 - 10.2.3 India
 - 10.2.3.1 Market Trends
 - 10.2.3.2 Market Forecast
 - 10.2.4 South Korea
 - 10.2.4.1 Market Trends
 - 10.2.4.2 Market Forecast
 - 10.2.5 Australia
 - 10.2.5.1 Market Trends
 - 10.2.5.2 Market Forecast
 - 10.2.6 Indonesia
 - 10.2.6.1 Market Trends
 - 10.2.6.2 Market Forecast
 - 10.2.7 Others
 - 10.2.7.1 Market Trends
 - 10.2.7.2 Market Forecast
 - 10.3 Europe
 - 10.3.1 Germany
 - 10.3.1.1 Market Trends
 - 10.3.1.2 Market Forecast
 - 10.3.2 France
 - 10.3.2.1 Market Trends
 - 10.3.2.2 Market Forecast
 - 10.3.3 United Kingdom
 - 10.3.3.1 Market Trends
 - 10.3.3.2 Market Forecast
 - 10.3.4 Italy
 - 10.3.4.1 Market Trends
 - 10.3.4.2 Market Forecast
 - 10.3.5 Spain

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
 - 10.3.6.1 Market Trends
 - 10.3.6.2 Market Forecast
- 10.3.7 Others
 - 10.3.7.1 Market Trends
 - 10.3.7.2 Market Forecast
- 10.4 Latin America
 - 10.4.1 Brazil
 - 10.4.1.1 Market Trends
 - 10.4.1.2 Market Forecast
 - 10.4.2 Mexico
 - 10.4.2.1 Market Trends
 - 10.4.2.2 Market Forecast
 - 10.4.3 Others
 - 10.4.3.1 Market Trends
 - 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
 - 10.5.1 Market Trends
 - 10.5.2 Market Breakup by Country
 - 10.5.3 Market Forecast
- 11 Drivers, Restraints, and Opportunities
 - 11.1 Overview
 - 11.2 Drivers
 - 11.3 Restraints
 - 11.4 Opportunities
- 12 Value Chain Analysis
- 13 Porters Five Forces Analysis
 - 13.1 Overview
 - 13.2 Bargaining Power of Buyers
 - 13.3 Bargaining Power of Suppliers
 - 13.4 Degree of Competition
 - 13.5 Threat of New Entrants
 - 13.6 Threat of Substitutes
- 14 Price Analysis
- 15 Competitive Landscape
 - 15.1 Market Structure
 - 15.2 Key Players
 - 15.3 Profiles of Key Players
 - 15.3.1 Amicus Therapeutics Inc.
 - 15.3.1.1 Company Overview
 - 15.3.1.2 Product Portfolio
 - 15.3.1.3 Financials
 - 15.3.1.4 SWOT Analysis
 - 15.3.2 Audentes Therapeutics Inc. (Astellas US Holding Inc.)
 - 15.3.2.1 Company Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.2.2 Product Portfolio
- 15.3.3 Oxyrane UK Limited
 - 15.3.3.1 Company Overview
 - 15.3.3.2 Product Portfolio
- 15.3.4 Sanofi S.A.
 - 15.3.4.1 Company Overview
 - 15.3.4.2 Product Portfolio
 - 15.3.4.3 Financials
 - 15.3.4.4 SWOT Analysis
- 15.3.5 Spark Therapeutics Inc.
 - 15.3.5.1 Company Overview
 - 15.3.5.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Pompe Disease Treatment Market by Treatment (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone-Advanced Replacement Therapy (CART), and Others), Route of Administration (Oral, Intravenous, and Others), Distribution Channel (Hospital and Clinics Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Indication Type (Infantile-Onset Pompe Disease (IOPD), Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Pompe Disease (LOPD), and Others), and Region 2024-2032

Market Report | 2024-01-30 | 142 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$3899.00
	Five User Licence	\$4899.00
	Enterprisewide License	\$5899.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-24"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com